ClinicalTrials.gg

Program

QLC5508

A development code. Also written as “QLC5508 (Investigational Product / Formulation T)” and “QLC5508 (Reference Product / Formulation R)”.

Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine · Prostatic Neoplasms · Esophageal Squamous Cell Carcinoma, led by Qilu Pharmaceutical.

Furthest: phase 3, since Mar 3, 20266 company-led studies, 6 open or runningNext primary completion: Dec 5, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical66 open or runningphase 3since Mar 3, 2026Sep 28, 2025Dec 5, 2026phase 1 · NCT07620041

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2025First study: phase 2 study in Advanced Solid TumorFirst studyNCT07256782 · 444 planned · China
  2. Mar 3, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaPhase 3 reachedNCT07463573 · 466 planned · China
  3. May 12, 2026Phase 1 study in Refractory or Relapsed Solid TumorsNCT07620041 · 48 planned · China
  4. Jun 2, 2026Phase 3 study in Prostatic NeoplasmsNCT07632690 · 700 planned
  5. Aug 30, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07802821 · 556 planned · China
  6. Oct 18, 2026Phase 3 study in Extrapulmonary Neuroendocrine CarcinomaNCT07894211 · 270 planned

Ahead

  1. Dec 5, 2026Primary completion: phase 1 study in Refractory or Relapsed Solid TumorsNCT07620041
  2. Jun 5, 2028Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT07463573
  3. Jun 20, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07632690
  4. Mar 15, 2029Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07802821

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07894211Extrapulmonary Neuroendocrine Carcinoma3Not yet recruitingMar 26, 2029270
NCT07802821Small Cell Lung Carcinoma · China3RecruitingMar 15, 2029556
NCT07632690Prostatic Neoplasms3Not yet recruitingJun 20, 2028700
NCT07620041Refractory or Relapsed Solid Tumors · China1RecruitingDec 5, 202648
NCT07463573Esophageal Squamous Cell Carcinoma · China3RecruitingJun 5, 2028466
NCT07256782Advanced Solid Tumor · China2RecruitingOct 2026444

How it is read

Names in the registry

  • “QLC5508”, 5 entries
  • “QLC5508 (Investigational Product / Formulation T)”, 1 entry
  • “QLC5508 (Reference Product / Formulation R)”, 1 entry

Codes read as this program: QLC5508.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.